Elevation Oncology Inc Cash Flow Conversion Efficiency
Elevation Oncology Inc cash flow conversion efficiency. Based on the latest financial reports, Elevation Oncology Inc (ELEV) has a cash flow conversion efficiency ratio of -0.272x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.71 Million) by net assets ($46.73 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Elevation Oncology Inc (2019–2024)
Cash flow conversion efficiency of Elevation Oncology Inc from 2019 to 2024. This chart illustrates how Elevation Oncology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Elevation Oncology Inc stock quote for real-time trading data and today's change.
Elevation Oncology Inc Cash Flow Conversion Ratio Explained
Elevation Oncology Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Elevation Oncology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Elevation Oncology Inc ranked by their cash flow conversion efficiency. Also see ELEV company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kafein Yazilim
IS:KFEIN
|
0.024x |
|
OB Holdings Berhad
KLSE:0327
|
0.053x |
|
HG Capital Trust PLC
LSE:HGT
|
-0.016x |
|
Niche Capital Emas Holdings
KLSE:7139
|
0.013x |
|
Accendra Health Inc
NYSE:ACH
|
-0.147x |
|
Motorsport Gaming Us LLC
NASDAQ:MSGM
|
0.214x |
|
Borneo Oil Bhd
KLSE:7036
|
-0.019x |
|
Lottery.com Inc.
NASDAQ:SEGG
|
-0.095x |
Annual Cash Flow Conversion Efficiency for Elevation Oncology Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Elevation Oncology Inc from 2019 to 2024. Review Elevation Oncology Inc financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $60.02 Million | $-36.36 Million | -0.606x | +40.90% |
| 2023-12-31 | $54.81 Million | $-56.18 Million | -1.025x | +41.21% |
| 2022-12-31 | $49.03 Million | $-85.48 Million | -1.743x | -713.12% |
| 2021-12-31 | $140.70 Million | $-30.17 Million | -0.214x | -140.24% |
| 2020-12-31 | $-23.08 Million | $-12.30 Million | 0.533x | -42.58% |
| 2019-12-31 | $-5.87 Million | $-5.45 Million | 0.928x | -- |
About Elevation Oncology Inc
Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. It's lead candidate is EO-3021, an antibody-drug conjugate (ADC) comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 monoclonal antibody (mAb) site-specifically conjugated with a cleavable link… Read more